Bio-Gene Technology Ltd
BGT.ASXMaterials
Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its unique technology is based on a naturally occurring class of chemicals prove
Market Data
$0.028
-0.0%$8.8M
-100000.0x
$-0.010
0.00%
-0.3%
Latest Earnings
Appendix 4D and Half-Year Accounts 31 December 2025
24 February 2026
Bio-Gene Technology reported a half-year loss of $1.4M (down 4.4% from prior year) while achieving significant operational milestones including OMRI approval for Qcide and positive efficacy data for Flavocide. Revenue surged 516% to $466K driven by R&D incentives and research grants, with the company raising $2.46M during the period to fund development programs. Key points: Qcide approved by US OMRI for listing as Botanical Pesticide under USDA National Organic Program; Positive Flavocide efficacy results showing >90% mortality of Lyme disease vector ticks within 24 hours; Awarded US$3.0M in grants from US Department of Defense under Deployed Warfighter Protection Program
Recent Announcements
Appendix 4D and Half-Year Accounts 31 December 2025
Bio-Gene Technology reported a half-year loss of $1.4M (down 4.4% from prior year) while achieving significant operational milestones including OMRI approval for Qcide and positive efficacy data for Flavocide. Revenue surged 516% to $466K driven by R&D incentives and research grants, with the company raising $2.46M during the period to fund development programs. Key points: Qcide approved by US OMRI for listing as Botanical Pesticide under USDA National Organic Program; Positive Flavocide efficacy results showing >90% mortality of Lyme disease vector ticks within 24 hours; Awarded US$3.0M in grants from US Department of Defense under Deployed Warfighter Protection Program
Get real-time alerts for BGT
Receive AI-powered earnings summaries and instant notifications when Bio-Gene Technology Ltd releases results.
Register Free